蒙药复方述达格-4特征图谱初步分析
x

请在关注微信后,向客服人员索取文件

篇名: 蒙药复方述达格-4特征图谱初步分析
TITLE:
摘要: 目的:分析蒙药复方述达格-4的特征图谱。方法:采用高效液相色谱法。色谱柱为 Agilent Extend C18,流动相为0.4%乙酸溶液-甲醇(梯度洗脱),流速为0.6 mL/min,检测波长为286 nm,柱温为30 ℃,进样量为20 μL。分别对复方述达格-4全方及各单味药体内外特征图谱进行分析和对比。结果:复方述达格-4全方体外特征图谱有47个峰;其体内特征图谱有24个峰,其中峰1、4、7~9、12、14、18~20、22、25、38~41、44、46对应的18个成分为体外直接入血成分;各单味药体内特征图谱中峰1、4、7、8、12、14、18~22、25、40、46来源于高良姜药材;峰14、18、19、22、44来源于木香药材;峰1、4、7~9、12、14、18、19、22来源于石菖蒲药材。结论:直接入血成分及代谢产物可能为复方述达格-4在体内发挥作用的有效成分;该方法可用于其特征图谱的分析。
ABSTRACT: OBJECTIVE: To analyse characteristic chromatograms of Mongolian Compound Shudage-4. METHODS: HPLC method was adopted. The determination was performed on Agilent Extend C18 with mobile phase consisted of 0.4% acetic acid solution-methanol (gradient elution) at the flow rate of 0.6 mL/min. The detection wavelength was set at 286 nm, and column temperature was 30 ℃. The sample size was 20 μL. The in vivo and in vitro characteristic chromatograms of allsquare of Compound Shudage-4 and single ingredients were analysed and compared respectively. RESULTS: Totally 47 peaks were identified from in vitro characteristic chromatograms of allsquare of Compound Shudage-4. There were 24 common peaks from in vivo characteristic chromatograms,among which 18 ingredients corresponding to common peaks 1, 4, 7-9, 12, 14, 18-20, 22, 25, 38-41, 44, 46 were direct blood components in vitro; peaks 1, 4, 7, 8, 12, 14, 18-22, 25, 40 and 46 of serum test sample were from Alpinia officinarum; peaks 14, 18, 19, 22, 44 were from Aucklandia lappa; peaks 1, 4, 7-9, 12, 14, 18, 19, 22 were from Acorus tatarinowii. CONCLUSIONS: Blood components and some metabolites may beallsquare of Compound Shudage-4. The method can be used for the analysis of characteristic chromatograons of it.
期刊: 2018年第29卷第22期
作者: 杜银飞,嵇增云,信莎莎,董玉
AUTHORS: DU Yinfei,JI Zengyun,XIN Shasha,DONG Yu
关键字: 蒙药;复方述达格-4;特征图谱;化学成分;体内;体外
KEYWORDS: Mongolian medicine; Compound Shudage-4; Characteristic chromatogram; Chemical component; in vivo; in vitro
阅读数: 217 次
本月下载数: 5 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!